MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline.
Speaking during an informal discussion hosted by Stifel senior biotech analyst Stephen Willey, Risser said MacroGenics has had “a good, strong start to the year” and is focused on sharpening its pipeline strategy, maximizing asset value and extending its financial runway.
